The clinical efficacy and safety of a drug is determined by its activity profile across many proteins in the proteome.
ex scientia is the first company to develop a systematic approach to tailoring drugs against polypharmacology profiles for superior clinical efficacy. This is achieved by either dialling-in extra desired targets to improve phenotypic response or removing unwanted off-targets to improve safety.
We focus on exploiting our advanced design technologies to the development of compounds with tailored selectivity and in particular a portfolio of bispecific drugs that tackle unmet medical need.
Our bispecific design technology delivers efficacious small molecules drugs binding novel target combinations, either within or between gene families. By hitting multiple nodes in the cellular network simultaneously better clinical efficacy can be achieved.
Non-specific, promiscuous interactions with undesired proteins frequently cause drug toxicity and adverse effects. Our tailored selectivity technology can be applied to the discovery of drug candidates with desired selectivity, thereby reducing side effects and toxicity.